Drug intelligence / Profile preview

PORT-9

Development stage: Discontinued
Lead developer: Cyncado Therapeutics
Modality: Small Molecules

Overview

PORT-9 is a small molecule adenosine receptor antagonist that was developed by Tarus Therapeutics and subsequently acquired by Portage Biotech. It was part of a pipeline of adenosine antagonists intended to address cancer treatment resistance by blocking immunosuppressive adenosine signaling, particularly in solid tumors and gastrointestinal cancers. The development of PORT-9 has since been discontinued.

Targets

ADORA2B (Adenosine A2B receptor)

Beyond the preview

Go deeper on PORT-9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PORT-9.

Explore the full profile